Related Experiment Video
Updated: May 15, 2026
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Small-molecule inducer of β cell proliferation identified by high-throughput screening
Weijun Shen1, Matthew S Tremblay, Vishal A Deshmukh
1Department of Chemistry, 10550 North Torrey Pines Road, The Scripps Research Institute, La Jolla, California 92037, United States.
Abstract:
The identification of factors that promote β cell proliferation could ultimately move type 1 diabetes treatment away from insulin injection therapy and toward a cure. We have performed high-throughput, cell-based screens using rodent β cell lines to identify molecules that induce proliferation of β cells. Herein we report the discovery and characterization of WS6, a novel small molecule that promotes β cell proliferation in rodent and human primary islets. In the RIP-DTA mouse model of β cell ablation, WS6 normalized blood glucose and induced concomitant increases in β cell proliferation and β cell number. Affinity pulldown and kinase profiling studies implicate Erb3 binding protein-1 and the IκB kinase pathway in the mechanism of action of WS6.
Insights
Researchers discovered WS6, a novel small molecule that promotes beta cell proliferation. This finding offers potential for type 1 diabetes treatment beyond insulin injections, moving towards a cure.
Area of Science:
- Endocrinology
- Molecular Biology
- Diabetes Research
Background:
- Type 1 diabetes (T1D) treatment currently relies on insulin therapy.
- Identifying factors that promote beta cell proliferation is crucial for developing T1D cures.
- Current T1D therapies do not address the underlying cause of beta cell destruction.
Purpose of the Study:
- To identify novel small molecules that stimulate beta cell proliferation.
- To characterize the effects of identified molecules on rodent and human beta cells.
- To investigate the therapeutic potential of WS6 in a mouse model of T1D.
Main Methods:
- High-throughput, cell-based screening of rodent beta cell lines.
- Characterization of WS6 in rodent and human primary islets.
- Assessment of WS6 efficacy in the RIP-DTA mouse model of beta cell ablation.
Main Results:
- WS6 was identified as a novel small molecule promoting beta cell proliferation.
- WS6 demonstrated efficacy in both rodent and human primary islets.
- In vivo studies showed WS6 normalized blood glucose and increased beta cell number in a T1D mouse model.
Conclusions:
- WS6 is a promising therapeutic candidate for T1D.
- WS6 promotes beta cell proliferation and regeneration.
- Further research into WS6's mechanism involving Erb3 binding protein-1 and IκB kinase pathway is warranted.
